Sign up USA
Proactive Investors - Run By Investors For Investors

Bellerophon Therapeutics reports positive mid-stage trial results for a treatment associated with COPD

The company said the phase 2 trial of its INOpulse inhaled nitric oxide met its primary and secondary goals, showing statistically significant improvement in six-minute walking distance, hemodynamics and blood vessel volume
COPD
Bellerophon Therapeutics said it is planning to conduct a larger phase 2b study of the treatment

Bellerophon Therapeutics Inc. (NASDAQ:BLPH) saw its shares jump in early trading after the company reported positive results in a mid-stage trial of a treatment for pulmonary hypertension associated with COPD (chronic obstructive pulmonary disease).

The company said the phase 2 trial of its INOpulse inhaled nitric oxide met its primary and secondary goals, showing statistically significant improvement in six-minute walking distance, hemodynamics and blood vessel volume.

In a statement, Dr. Raymond L. Benza of the Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA and chairman of Bellerophon's PH-COPD steering committee said: "COPD patients with associated pulmonary hypertension have a poor prognosis with an approximately 4-year life expectancy and high hospitalization rates, which represents a significant unmet medical need for a safe and effective long-term treatment."

The company said it is planning to conduct a larger phase 2b study of the treatment.

In early New York trading, Bellerophon shares were up 8% at US$1.2018 before later in the day, gaining over 5% to $1.19.

View full BLPH profile View Profile

Bellerophon Therapeutics Timeline

Related Articles

clinical-trial.jpg
June 30 2017
In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
Patient undergoing radiotherapy
August 02 2017
Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology
generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use